Skip to main content
    S

    Septerna, Inc. Common Stock (SEPN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $41.67
    -0.93 (-2.18%)

    Market Cap: $2.03B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Septerna, Inc. Common Stock (SEPN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Septerna, Inc. Common Stock are Sarepta Therapeutics (SRPT), Ultragenyx (RARE) and Vera Therapeutics (VERA). By market cap, Septerna, Inc. Common Stock ranks 4th of the 13 companies on this page; Legend Biotech (LEGN) is the largest at $3.39B.

    Peer Comparison

    SEPN's revenue growth of -12.2% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Recursion Pharmaceuticals Inc (RXRX)$1.99BN/A23.1x0.0%-51.8%258.5%0.00%
    Zenas BioPharma, Inc. Common Stock (ZBIO)$1.90BN/A168.0x0.0%-104.3%-100.0%0.00%
    Novavax Inc (NVAX)$1.41BN/A3.2x-18.6%-66.6%-3.0%0.00%
    Palvella Therapeutics, Inc (PVLA)$2.23BN/AN/A0.0%N/A0.0%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Peer median$1.71B266.5x6.0x-0.0%-59.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Septerna, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Recursion Pharmaceuticals Inc (RXRX)
    Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry...
    RXRX competitors
    Zenas BioPharma, Inc. Common Stock (ZBIO)
    Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based...
    ZBIO competitors
    Novavax Inc (NVAX)
    Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases...
    NVAX competitors
    Palvella Therapeutics, Inc (PVLA)
    Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from...
    PVLA competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors

    Frequently Asked Questions About SEPN

    Who are Septerna, Inc. Common Stock's main competitors?

    The companies most similar to Septerna, Inc. Common Stock include Sarepta Therapeutics (SRPT), Ultragenyx (RARE), Vera Therapeutics (VERA), Nuvation Bio (NUVB) and Nektar Therapeutics (NKTR), listed from the closest match.

    Who is Septerna, Inc. Common Stock's biggest competitor?

    Legend Biotech (LEGN) is the largest of the similar companies at $3.39B; Sarepta Therapeutics (SRPT) is the closest match by business profile, size, sector and industry.

    How does SEPN stock compare with its competitors?

    SEPN's P/S is 20.3x against a peer median of 6.0x; its net margin is -61.3% against a peer median of -0.0%.

    Which of Septerna, Inc. Common Stock's competitors pays a higher dividend?

    Septerna, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Septerna, Inc. Common Stock bigger than its competitors?

    No. Septerna, Inc. Common Stock is 4th by market cap among the 13 companies on this page; the largest is Legend Biotech (LEGN) at $3.39B.